The European Patent Office (EPO) has published patent application EP4397683A1, titled 'Anti-Human Interleukin-33 Monoclonal Antibody and Use Thereof'. The application was filed by Qyuns Therapeutics Co., Ltd. and details a specific monoclonal antibody targeting human Interleukin-33, along with its potential therapeutic applications. This publication represents the granting of a patent or the publication of a pending application.

This patent publication does not impose new regulatory obligations on companies. However, it is relevant for entities operating in the pharmaceutical and biotechnology sectors, particularly those involved in research and development of treatments for conditions related to Interleukin-33, such as allergies and inflammatory diseases. Companies should be aware of this patent for potential intellectual property considerations, licensing opportunities, or freedom-to-operate analyses.